Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 500674 | NSE Symbol : SANOFI | ISIN : INE058A01010 | Industry : Pharmaceuticals - Multinational |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
18-Mar-2025	18-Mar-2025	AGM	The Board has approved the re-appointment of Mr. Rahul Bhatnagar as an Independent Director of the Company for a second term of five consecutive years, subject to the approval of the members at the ensuing AGM.
13-Feb-2025	27-Feb-2025	Final Dividend	Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/02/2025 inter alia to consider and approve the Audited Finacial Statements (Standalone & Consolidated) for the Quarter and Financial Year ended 31st December 2024 and Recommendation of Final Dividend if any. We enclose a copy of the approved Standalone and Consolidated Financial Results for the Quarter and Financial Year Ended 31St December 2024 and recommended Final dividend of Rs. 117/- per equity share of face value of Rs. 10 each. (As Per BSE Announcement Dated 27.02.2025) The Board has approved the Record Date for the Final Dividend for Financial Year ended 31st December 2024 (As per BSE Announcement Dated on 18/03/2025)
11-Feb-2025	11-Feb-2025	Change in Other Executives	Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for appointment of Company Secretary and Compliance Officer
17-Oct-2024	07-Nov-2024	Quarterly Results	Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2024 inter alia to consider and approve the Unaudited Financial Statements (Standalone & Consolidated) for the quarter and nine months ended 30th September 2024. We refer to our letter dated 17th October 2024 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e., Thursday, 7th November 2024, inter-alia considered and approved Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 30th September 2024. A copy of the Press Release issued in this regard is enclosed. (As Per BSE Announcement dated on 07.11.2024)
08-Jul-2024	26-Jul-2024	Quarterly Results	Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2024 inter alia to consider and approve the Unaudited Financial Statements (Standalone & Consolidated) for the quarter and half year ended 30th June 2024. We refer to our letter dated 8th July 2024 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e., Friday, 26th July 2024, inter-alia considered and approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th June 2024. A copy of the Press Release issued in this regard is enclosed. Enclosed (As per BSE Announcement Dated on 26/07/2024)
26-Apr-2024	13-May-2024	Quarterly Results	Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2024 inter alia to consider and approve the Unaudited Financial Statements (Standalone & Consolidated) for the Quarter ended 31st March 2024. We wish to inform you that the Board of Directors at its meeting held today i.e. Monday, 13th May 2024, based on the recommendation of the Nomination and Remuneration Committee, have approved the appointment of Mr. Eric Mansion as a Non-Executive Director of the Company with effect from 3rd June 2024, subject to the approval of the Members of the Company through Postal Ballot. Unaudited standalone and consolidated financial results for the quarter ended 31st March 2024. (As Per BSE Announcement Dated on 13/05/2024)
24-Jan-2024	23-Feb-2024	Accounts	Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/02/2024 inter alia to consider and approve the Audited Financial Statements (Standalone & Consolidated) for the Quarter and Financial Year ended 31st December 2023 and recommend of dividend if any for the Financial Year ended 31st December 2023. The Board, at its meeting held on 23rd February, 2024, has declared an Interim Dividend of Rs. 50 per equity share and recommended a Final Dividend of Rs. 117 per equity share. Kindly refer the attachment for further details on payment date. We enclose a copy of the Auditor''s report and Audited Standalone and Consolidated Financial Results of the Company for the Financial Year ended 31st December 2023 along with Statement of Assets and Liabilities as on that date and Statement of Cashflows for the year ended 31st December 2023 as required under Regulation 33 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015. Further, the Board has also declared an Interim Dividend of Rs. 50 per equity share and recommended a final dividend of Rs. 117 per equity share. We enclose a copy of the Auditor''s Report and Audited Standalone and Consolidated Financial Results of the Company for the Financial Year ended 31st December 2023 along with the statement of assets and liabilities and statement of cashflows as on that date as required under Regulation 33 of the SEBI (LODR) Regulations, 2015. (As Per BSE Announcement dated on 23.02.2024)
19-Oct-2023	08-Nov-2023	Quarterly Results	Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the meeting of the Board of Directors of the Company will be held on Wednesday 8th November 2023; inter-alia to consider the Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 30th September 2023. Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we enclose a copy of Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 30th September 2023 approved at the board meeting along with a copy of Limited Review Report. Results- Financials Results for September 30 2023 Change in Chief Financial Officer (CFO) and Whole-time Director of the company Change in Chief Financial Officer and Whole-Time Director (As Per BSE Announcement Dated on 08/11/2023)
26-Sep-2023	26-Sep-2023	Change in Directors	Change in Director
26-Jul-2023	10-Aug-2023	Quarterly Results	Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 inter alia to consider and approve unaudited financial results for the quarter and half year ended 30th June 2023. SANOFI INDIA LIMITED has informed BSE about Board Meeting to be held on 10 Aug 2023 to consider financial statements for the period ended June 2023. Financial results. Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we enclose a copy of Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th June 2023 approved at this meeting along with a copy of Limited Review Report. Also enclosed is a copy of Press Release issued in this regard. Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th June 2023 (As Per BSE Announcement dated on 10.08.2023)
11-Apr-2023	10-May-2023	Quarterly Results	Quarterly Results Sanofi India Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2023 ,inter alia, to consider and approve the Unaudited Financial Results for the quarter ended 31st March 2023. (As Per BSE Announcement dated on 11.04.2023) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of the Unaudited Financial Results for the quarter ended 31st March 2023 approved at the Meeting held today with a copy of the Limited Review Report duly signed by the Auditors of the Company The Board of Directors of Sanofi India Limited, at its meeting held today, has approved a scheme of arrangement under Sections 230 to 232 of the Companies Act, 2013, to demerge its Consumer Healthcare Business from the Demerged Company into its wholly-owned subsidiary Sanofi Consumer Healthcare India Limited (currently under the process of incorporation) ('SCHIL /Resulting Company'). The detailed disclosures pertaining to the Scheme are captured in the attachment. (As Per BSE Announcement Dated on 10/05/2023)
07-Feb-2023	23-Feb-2023	Accounts	Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/02/2023 inter alia to consider and approve 1) the audited accounts for the quarter and year ended 31st December 2022 and 2) recommend dividend if any for the financial year ended 31st December 2022. Recommended a final dividend of Rs. 194/- per equity share of the face value of Rs.10/- each and a second special dividend of Rs. 183/- per equity share of the face value of Rs.10/- each for the financial year ended 31st December 2022, subject to approval by the Shareholders at the 67th Annual General Meeting. The Company had earlier paid one-time special interim dividend of Rs. 193/- per equity share on 22nd August 2022. 2. The total dividend for the financial year 2022, including the proposed final dividend, one-time special interim dividend and second special dividend, amounts to Rs. 570/- per equity share of the face value of Rs.10/- each. The Dividend, if approved by the Shareholders will be paid on or after 22nd May 2023; We refer to our letter dated 7th February 2023 informing you of our Board Meeting that was scheduled today. In this regard, we would like to inform you that the Board of Directors at its meeting held today i.e., Thursday, 23rd February 2023, inter-alia considered and approved matters as per attached documents. We refer to our letter dated 7th February 2023 informing you of our Board Meeting that was scheduled today. In this regard, we would like to inform you that the Board of Directors at its meeting held today i.e., Thursday, 23rd February 2023, inter-alia considered and: 1. Approved the financial results of the Company for the quarter and year ended 31st December 2022; Accordingly, we enclose a copy of the auditor's report and audited financial results of the Company for the quarter and year ended 31st December 2022 along with statement of assets and liabilities as on that date and statement of cashflows for the year ended 31st December 2022 as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information. We would like to inform you that the Board of Directors at its meeting held today i.e., Thursday, 23rd February 2023, considered and approved convening of the 67th AGM of the Company on Thursday, 11th May 2023 through Video Conferencing / Other Audio-Visual Means (VC/ OAVM) Further details of the AGM will be provided in the notice of the AGM which will be issued in due course. (As Per BSE Announcement Dated on 23.02.2023)
21-Oct-2022	03-Nov-2022	Quarterly Results	Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2022 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the meeting of the Board of Directors of the Company will be held on Thursday 3rd November 2022; inter alia to consider the unaudited financial results for the quarter and nine months ended 30th September 2022. Further to our intimation on 30th September 2022 this is to inform you that as per the 'Sanofi India Limited - Code of Conduct to Regulate Monitor and Report Trading by Designated Persons the trading window of the Company which was closed from 1st October 2022 for publication of financial results of the Company for the quarter and nine months ended 30th September 2022 shall remain closed up to Saturday 5th November 2022 (inclusive of both days). We refer to our letter dated 21st October 2022, informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 02.00 p.m. and concluded at 5.00 p.m. The Board approved Unaudited Financial Results for the quarter and nine months ended 30th September 2022. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of the Unaudited Financial Results for the quarter and nine months ended 30th September 2022 approved at this Meeting with a copy of the Limited Review Report duly signed by the Auditors of the Company. Pursuant to the requirements of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the the Board of Directors at its meeting held today i.e., 3rd November 2022 noted the resignation of Mr. Charles Billard and based on the recommendation of the Nomination and Remuneration Committee, approved the appointment of Ms. Annapurna Das (DlN: 08634664) as an Additional and Non-Executive (Non-Independent) Director of the Company with effect from 3rd November 2022. The said appointment will be subject to the approval of the Members of the Company through Postal Ballot. (As per BSE Announcement Dated on 03/11/2022)
06-Jul-2022	26-Jul-2022	Quarterly Results	Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2022 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the meeting of the Board of Directors of the Company will be held on Tuesday 26th July 2022; inter alia to consider the unaudited financial results for the quarter and half year ended 30th June 2022 (Q2). Further to our intimation on 27th June 2022 this is to inform you that as per the 'Sanofi India Limited- Code of Conduct to Regulate Monitor and Report Trading by Designated Persons the trading window of the Company which was closed from 1st July 2022 for publication of financial results of the Company for the quarter ended 30th June 2022 shall remain closed up to Thursday 28th July 2022 (inclusive of both days). Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2022 ,inter alia, to consider and approve Update We refer to our earlier letter dated 6th July 2022 informing about Company''s Board meeting to be held on 26th July 2022. We would also like to inform you that at the said meeting the Board of Directors will also consider declaration of One-time Special Interim Dividend for the year ending 31st December 2022. The interim dividend, if declared, shall be paid to the equity shareholders of the Company whose names appear on the Register of Members of the Company or in the records of the Depositories as beneficial owners of the shares as on Monday, 8th August 2022 which is the Record Date fixed for the purpose. (As Per BSE Announcement Dated on 13.07.2022) Dear Sirs, The Board of Directors of the Company at its Meeting held today has declared One-Time Special Interim Dividend of Rs. 193 per equity share of Rs. 10 each for the financial year ending 31st December 2022. The Meeting of Board of Directors commenced at 2.00 p.m. and concluded at 5.10 p.m. As informed earlier the Company has fixed 8th August 2022 as the record date for the purpose of payment of the One-Time Special Interim Dividend. The said dividend will be paid on or after 22nd August 2022 We refer to our letter dated 6th July 2022 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 02.00 p.m. and concluded at 5.10 p.m. The Board approved unaudited financial results for the quarter and half year ended 30th June 2022. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of the unaudited financial results for the quarter and half year ended 30th June 2022 approved at this Meeting including the Statement of Assets and Liabilities as on that date and the Statement of Cash Flow for the half year ended 30th June 2022 along with a copy of the Limited Review Report duly signed by the Auditors of the Company. (As Per BSE Announcement Dated on 26.07.2022)
07-Apr-2022	26-Apr-2022	Quarterly Results	Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/04/2022 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the meeting of the Board of Directors of the Company will be held on Tuesday 26th April 2022; inter alia to consider the unaudited financial results for the quarter ended 31st March 2022 (Q1). Further to our intimation on 28th March 2022 this is to inform you that as per the 'Sanofi India Limited- Code of Conduct to Regulate Monitor and Report Trading by Designated Persons the trading window of the Company which was closed from 1st April 2022 for publication of financial results of the Company for the quarter ended 31st March 2022 shall remain closed up to Thursday 28th April 2022 (inclusive of both days). We refer to our letter dated 7th April 2022 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 12.00 noon and concluded at 2.15 p.m. The Board approved unaudited financial results for the quarter ended 31st March 2022. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of the unaudited financial results for the quarter ended 31st March 2022 approved at this Meeting along with a copy of the Limited Review Report for your information. Please take the above information on record (As Per BSE Announcement Dated on 26.04.2022) In terms of Regulation 30 of the SEBI Listing Regulations, we hereby inform that the Board of Directors at its meeting held on 26th April 2022, approved conducting of Postal Ballot for seeking the approval of members for appointment of Mr. Rodolfo Hrosz as Managing Director of the Company w.e.f 1st June 2022 by passing an Ordinary Resolution. The Board of Directors have also appointed Mr. Makarand M. Joshi, Partner or failing him Ms. Kumudini Bhalerao, Partner at M/s Makarand M. Joshi & Co., Practicing Company Secretaries, who have given the consent to act as the Scrutinizer, for conducting the Postal Ballot process. The Company shall further intimate the Stock Exchanges on dispatch of the Postal Ballot notice. The Calendar of Events for the proposed postal ballot process is attached for your reference (As Per BSE Announcement Dated on 27.04.2022)

1 2

LOGIN HERE

Sanofi India Ltd

Board Meeting